Therapeutic targeting of B cells for rheumatic autoimmune diseases

Pharmacological Reviews

Volumn 63, Issue 1, 2011, Pages 127-156

  Engel, Pablo ^a,b   Gómez Puerta, Jose A ^a   Ramos Casals, Manuel ^a,b   Lozano, Francisco ^a,b   Bosch, Xavier ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ATACICEPT; AUTOANTIBODY; BELIMUMAB; CYCLOPHOSPHAMIDE; EPRATUZUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; MDX 1342; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HB12; OCRELIZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; SBI 087; TOCILIZUMAB; TRU 015; UNCLASSIFIED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BRONCHOSPASM; CELL SURVIVAL; CLINICAL TRIAL; COUGHING; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TARGETING; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; JOINT SWELLING; LIMB PAIN; MEMORY CELL; MYOSITIS; NONHUMAN; PATHOGENESIS; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SJOEGREN SYNDROME; SNEEZING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THROAT IRRITATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; RHEUMATIC DISEASES;

EID: 79952024055     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.109.002006     Document Type: Review

References (265)

1. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, and Shlomchik MJ (2007) Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179:3351-3361.
2. Alugupalli KR, Leong JM, Woodland RT, Muramatsu M, Honjo T, and Gerstein RM (2004) B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 21:379-390. (Pubitemid 39208339)
3. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, and Sanz I (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50:3580-3590. (Pubitemid 39488683)
4. Askenase PW, Szczepanik M, Itakura A, Kiener C, and Campos RA (2004) Extravascular T-cell recruitment requires initiation begun by Valpha14+ NKT cells and B-1 B cells. Trends Immunol 25:441-449. (Pubitemid 38951086)
5. Bartholdy B and Matthias P (2004) Transcriptional control of B cell development and function. Gene 327:1-23. (Pubitemid 38186644)
6. Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, et al. (2010) Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum 62:2443-2457.
7. Bermúdez A, Marco F, Conde E, Mazo E, Recio M, and Zubizarreta A (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894-895.
8. Bertrand FE, Eckfeldt CE, Fink JR, Lysholm AS, Pribyl JA, Shah N, and LeBien TW (2000) Microenvironmental influences on human B-cell development. Immunol Rev 175:175-186. (Pubitemid 30427167)
9. Bettelli E, Oukka M, and Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8:345-350.
10. Bichard P, Ounanian A, Girard M, Baccard C, Rolachon A, Renversez JC, Cordonnier D, Seigneurin JM, Debru JL, and Zarski JP (1994) High prevalence of hepatitis C virus RNA in the supernatant and the cryoprecipitate of patients with essential and secondary type II mixed cryoglobulinemia. J Hepatol 21:58-63. (Pubitemid 24236681)
11. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, and Mauri C (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32:129-140.
12. Blank M and Shoenfeld Y (2007) B cell targeted therapy in autoimmunity. J Autoimmun 28:62-68. (Pubitemid 46680498)
13. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester GR, et al. (2007) Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46:1191-1199. (Pubitemid 47053782)
14. Bosch X, Guilabert A, Espinosa G, and Mirapeix E (2008) Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol 29:280-289.
15. Bosch X, Guilabert A, and Font J (2006) Antineutrophil cytoplasmic antibodies. Lancet 368:404-418. (Pubitemid 44108124)
16. Bouaziz JD, Yanaba K, and Tedder TF (2008) Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 224:201-214.
17. Burnet M (1957) A modification of Jerne's theory of antibody production using the concept of clonal selection. Aust J Sci 20:67-69.
18. Cacoub P, Delluc A, Saadoun D, Landau DA, and Sene D (2008) Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 67:283-287.
19. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, and Stohl W (2008) B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 67:1011-1016. (Pubitemid 351956665)
20. Cancro MP, D'Cruz DP, and Khamashta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 119:1066-1073.
21. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357.
22. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806. (Pubitemid 44497758)
23. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, and Ahmed R (2003) Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171:4969-4973. (Pubitemid 37432774)
24. Chan OT, Hannum LG, Haberman AM, Madaio MP, and Shlomchik MJ (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189:1639-1648.
25. Chaudhuri J and Alt FW (2004) Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol 4:541-552.
26. Chung L, Genovese MC, and Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143:763-767. (Pubitemid 46955736)
27. Dall'Era M and Wofsy D (2010) Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol 6:124-125.
28. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, and Andonopoulos AP (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 49:271-280.
29. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, and Emery P (2008) Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67:1541-1544.
30. Dervite I, Hober D, and Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69. (Pubitemid 32064857)
31. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, RoueIQ, et al. (2007) Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57:310-317. (Pubitemid 47164095)
32. Dighiero G (1997) Natural autoantibodies, tolerance, and autoimmunity. Ann NY Acad Sci 815:182-192.
33. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, and Tedder TF (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180:361-371.
34. DiLillo DJ, Matsushita T, and Tedder TF (2010) B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann NY Acad Sci 1183:38-57.
35. Ding C and Jones G (2006) Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline. Curr Opin Investig Drugs 7:464-472. (Pubitemid 43772987)
36. Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G, and International Roundtable on B cells as Therapeutic Target for Intervention (2009a) Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 9:82-89.
37. Dörner T, Jacobi AM, and Lipsky PE (2009b) B cells in autoimmunity. Arthritis Res Ther 11:247.
38. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, and Burmester GR (2006) Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8:R74.
39. Dörner T and Lipsky PE (2006) Signalling pathways in B cells: implications for autoimmunity. Curr Top Microbiol Immunol 305:213-240. (Pubitemid 47400260)
40. Dörner T, Radbruch A, and Burmester GR (2009c) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5:433-441.
41. Driver CB, Ishimori M, and Weisman MH (2008) The B cell in systemic lupus erythaematosus: a rational target for more effective therapy. Ann Rheum Dis 67:1374-1381.
42. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, and Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581. (Pubitemid 38758544)
43. Ehrhardt GR, Davis RS, Hsu JT, Leu CM, Ehrhardt A, and Cooper MD (2003) The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci USA 100:13489-13494. (Pubitemid 37444769)
44. Ekland EH, Forster R, Lipp M, and Cyster JG (2004) Requirements for follicular exclusion and competitive elimination of autoantigen-binding B cells. J Immunol 172:4700-4708. (Pubitemid 38456390)
45. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, and Noelle RJ (2009) Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229:152-172.
46. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390-1400.
47. Engel P, Wagner N, Miller AS, and Tedder TF (1995a) Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp Med 181:1581-1586.
48. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, and Tedder TF (1995b) Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3:39-50.
49. Falk RJ, Terrell RS, Charles LA, and Jennette JC (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115-4119. (Pubitemid 20217992)
50. Fecteau JF, Côté G, and Néron S (2006) A new memory CD27-IgG+ B cell population in peripheral blood expressing VH genes with low frequency of somatic mutation. J Immunol 177:3728-3736. (Pubitemid 44359905)
51. Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, and Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56:1417-1423. (Pubitemid 46764068)
52. Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, Kyburz D, Dudler J, Gabay C, and Arthritis (2010) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative antitumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:387-393.
53. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356-361.
54. Fleischmann RM (2009) Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 38:265-280.
55. Fleischmann R, Cohen S, Pardo P, Shaw M, Bhattacharya I, Sridhara S, Diehl A, and Gourley I (2010) B cell depletion in subjects with controlled systemic lupus erythematosus (SLE) after intravenous or subcutaneous administration of SBI-087. Ann Rheum Dis 69 (Suppl. 3):550.
56. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, et al. (2008) Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 10:R109.
57. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, et al. (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61:1143-1151.
58. Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, and Defrance T (2007) TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 178:7779-7786. (Pubitemid 46898049)
59. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, et al. (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58:2652-2661.
60. Golbin JM and Specks U (2007) Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA-associated vasculitis. Clin Exp Rheumatol 25:S74-76.
61. Gómez-Puerta JA and Bosch X (2009) Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am J Pathol 175:1790-1798.
62. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, et al. (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817-826. (Pubitemid 40094277)
63. Gonzalez M, Mackay F, Browning JL, Kosco-Vilbois MH, and Noelle RJ (1998) The sequential role of lymphotoxin and B cells in the development of splenic follicles. J Exp Med 187:997-1007. (Pubitemid 28176400)
64. Good KL, Avery DT, and Tangye SG (2009) Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol 182:890-901.
65. Goodnow CC, Campbell JA, Rui L, and Vinuesa CG (2007) Tolerance mechanisms in the late phase of the antibody response. Adv Exp Med Biol 596:163-168.
66. Goodnow CC, Sprent J, Fazekas de St Groth B, and Vinuesa CG (2005) Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435:590-597. (Pubitemid 40825498)
67. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, et al. (2006) Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci USA 103:2770-2775.
68. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, and Lipsky PE (2003) Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 112:1506-1520.
69. Green MC, Sweet HO, and Bunker LE (1976) Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 82:493-512.
70. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, et al. (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109:59-68. (Pubitemid 34052542)
71. Haas KM, Poe JC, Steeber DA, and Tedder TF (2005) B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23:7-18. (Pubitemid 41019653)
72. Haas KM, Watanabe R, Matsushita T, Nakashima H, Ishiura N, Okochi H, Fujimoto M, and Tedder TF (2010) Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. J Immunol 184:4789-4800.
73. Haddad EA, Senger LK, and Takei F (2009) An accessory role for B cells in the IL-12-induced activation of resting mouse NK cells. J Immunol 183:3608-3615.
74. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, and Tedder TF (2005) The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 174:4389-4399. (Pubitemid 40396022)
75. Hardy RR (2006) B-1 B cells: development, selection, natural autoantibody and leukemia. Curr Opin Immunol 18:547-555.
76. Harris DP, Goodrich S, Mohrs K, Mohrs M, and Lund FE (2005) Cutting edge: the development of IL-4-producing B cells (B effector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and Th2 cells. J Immunol 175:7103-7107. (Pubitemid 41713402)
77. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain SL, and Lund FE (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1:475-482.
78. Hasegawa M (2010) B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 37:3-10.
79. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, et al. (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954-966. (Pubitemid 44411958)
80. Haynes NM, Allen CD, Lesley R, Ansel KM, Killeen N, and Cyster JG (2007) Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J Immunol 179:5099-5108.
81. Human Genome Sciences Press Release (2009) Human Genome Sciences and GlaxoSmithKline Announce full presentation at ACR of positive phase 3 study results for Benlysta in systemic lupus erythematosus. Available at: http://www.hgsi.com/latest/human-genome-sciences-and-glaxosmithkline-announce- positive-results-insecond-of-two-phase-3-trials-of-benlysta-in-systemic-lupus- erythema-8.html.
82. Inoue S, Leitner WW, Golding B, and Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66:7741-7747. (Pubitemid 44289234)
83. Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N, Sellam J, Lepajolec C, and Mariette X (2006) B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther 8:R51.
84. Jackson SM, Wilson PC, James JA, and Capra JD (2008) Human B cell subsets. Adv Immunol 98:151-224.
85. Jacob N and Stohl W (2010) Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 43:84-97.
86. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, and Dörner T (2008) Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 67:450-457. (Pubitemid 351498422)
87. Jamin C, Morva A, Lemoine S, Daridon C, de Mendoza AR, and Youinou P (2008) Regulatory B lymphocytes in humans: a potential role in autoimmunity. Arthritis Rheum 58:1900-1906. (Pubitemid 351988080)
88. Jankovic D, Cheever AW, Kullberg MC, Wynn TA, Yap G, Caspar P, Lewis FA, Clynes R, Ravetch JV, and Sher A (1998) CD4+ T cell-mediated granulomatous pathology in schistosomiasis is downregulated by a B cell-dependent mechanism requiring Fc receptor signaling. J Exp Med 187:619-629. (Pubitemid 28093364)
89. Jones ED, Hashim FA, Creagh FM, Williams SE, and Smith BR (1985) The interaction between the TSH receptor and Graves' sera with TSH agonist or antagonist properties. Mol Cell Endocrinol 41:257-261. (Pubitemid 15022751)
90. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, et al. (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211-220.
91. Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, and Atkinson J (2010) Immunologic rheumatic disorders. J Allergy Clin Immunol 125:S204-215.
92. Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, Guias B, Pennec Y, Pers JO, Daridon C, Jamin C, Renaudineau Y, Roué IQ, et al. (2007) Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biologics 1:311-319.
93. Jung D, Giallourakis C, Mostoslavsky R, and Alt FW (2006) Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol 24:541-570.
94. Kahn P, Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Factor SM, and Davidson A (2008) Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 58:2824-2834.
95. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA, Davidovits A, Raab I, Jahn R, Ashour O, et al. (2008) Molecular mimicry in pauciimmune focal necrotizing glomerulonephritis. Nat Med 14:1088-1096.
96. Katz SI, Parker D, and Turk JL (1974) B-cell suppression of delayed hypersensitivity reactions. Nature 251:550-551.
97. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, Wei N, and Boyle DL (2008) Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 67:402-408.
98. Keogh KA, Wylam ME, Stone JH, and Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262-268. (Pubitemid 40129256)
99. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kvien TK, et al. (2009) Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68:216-221.
100. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, et al. (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896-3908. (Pubitemid 350262316)
101. King C, Tangye SG, and Mackay CR (2008) T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 26:741-766. (Pubitemid 351600391)
102. Koffler D, Agnello V, Thoburn R, and Kunkel HG (1971) Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med 134:169s-179s.
103. Kosco-Vilbois MH and Scheidegger D (1995) Follicular dendritic cells: antigen retention, B cell activation, and cytokine production. Curr Top Microbiol Immunol 201:69-82.
104. Kotzin BL (2005) The role of B cells in the pathogenesis of rheumatoid arthritis. J Rheumatol Suppl 73:14-18; discussion 29-30.
105. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, and Mathis D (1996) Organ-specific disease provoked by systemic autoimmunity. Cell 87:811-822. (Pubitemid 26404281)
106. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, and Meinl E (2005) BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 25:298-302. (Pubitemid 41642976)
107. Küppers R, Klein U, Hansmann ML, and Rajewsky K (1999) Cellular origin of human B-cell lymphomas. N Engl J Med 341:1520-1529. (Pubitemid 29526356)
108. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, and Simms RW (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578-583.
109. Lafyatis R, O'Hara C, Feghali-Bostwick CA, and Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56:3167-3168. (Pubitemid 47502765)
110. Lamprecht P, Till A, Steinmann J, Aries PM, and Gross WL (2007) Current state of biologicals in the management of systemic vasculitis. Ann NY Acad Sci 1110:261-270. (Pubitemid 350043015)
111. Landau DA, Saadoun D, Calabrese LH, and Cacoub P (2007) The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 6:581-587. (Pubitemid 47374619)
112. Lanzavecchia A (1987) Antigen uptake and accumulation in antigen-specific B cells. Immunol Rev 99:39-51.
113. Lanzavecchia A and Sallusto F (2009) Human B cell memory. Curr Opin Immunol 21:298-304.
114. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, and Mariette X (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66:700-703. (Pubitemid 46707145)
115. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, and Mariette X (2008) B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand J Immunol 67:185-192.
116. Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, and Edwards JC (2007) Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 46:29-36. (Pubitemid 44932780)
117. Levesque MC (2009) Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol 157:198-208.
118. Levine MH, Haberman AM, Sant'Angelo DB, Hannum LG, Cancro MP, Janeway CA Jr, and Shlomchik MJ (2000) A B-cell receptor-specific selection step governs immature to mature B cell differentiation. Proc Natl Acad Sci USA 97:2743-2748. (Pubitemid 30159242)
119. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601-607.
120. Li Y, Li H, and Weigert M (2002) Autoreactive B cells in the marginal zone that express dual receptors. J Exp Med 195:181-188. (Pubitemid 34461262)
121. Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764-766.
122. Longerich S, Basu U, Alt F, and Storb U (2006) AID in somatic hypermutation and class switch recombination. Curr Opin Immunol 18:164-174. (Pubitemid 43327298)
123. Looney RJ (2010) B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 70:529-540.
124. Looney RJ, Anolik J, and Sanz I (2004) B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 13:381-390. (Pubitemid 38788501)
125. Lopes-Carvalho T, Foote J, and Kearney JF (2005) Marginal zone B cells in lymphocyte activation and regulation. Curr Opin Immunol 17:244-250. (Pubitemid 40692658)
126. Lorenz RG, Chaplin DD, McDonald KG, McDonough JS, and Newberry RD (2003) Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J Immunol 170:5475-5482. (Pubitemid 36617835)
127. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, and Isenberg DA (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61:482-487.
128. Lund FE (2008) Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 20:332-338.
129. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, and Browning JL (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190:1697-1710. (Pubitemid 30002351)
130. MacLennan IC, Toellner KM, Cunningham AF, Serre K, Sze DM, Zúñiga E, Cook MC, and Vinuesa CG (2003) Extrafollicular antibody responses. Immunol Rev 194:8-18. (Pubitemid 36886424)
131. Mamani-Matsuda M, Cosma A, Weller S, Faili A, Staib C, Garçon L, Hermine O, Beyne-Rauzy O, Fieschi C, Pers JO, et al. (2008) The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 111:4653-4659.
132. Mandik-Nayak L, Racz J, Sleckman BP, and Allen PM (2006) Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J Exp Med 203:1985-1998. (Pubitemid 44188472)
133. Maniati E, Potter P, Rogers NJ, and Morley BJ (2008) Control of apoptosis in autoimmunity. J Pathol 214:190-198. (Pubitemid 351160156)
134. Manjarrez-Orduño N, Quá ch TD, and Sanz I (2009) B cells and immunological tolerance. J Invest Dermatol 129:278-288.
135. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, and Kimberly R (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 62:168-171. (Pubitemid 36135394)
136. Mårtensson IL, Keenan RA, and Licence S (2007) The pre-B-cell receptor. Curr Opin Immunol 19:137-142. (Pubitemid 46356967)
137. Martin F and Chan AC (2004) Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517-527. (Pubitemid 38638122)
138. Martin F and Kearney JF (2000) B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol Rev 175:70-79.
139. Martin F and Kearney JF (2001) B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 13:195-201. (Pubitemid 32176039)
140. Martin F and Kearney JF (2002) Marginal-zone B cells. Nat Rev Immunol 2:323-335. (Pubitemid 37328755)
141. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, Mathis D, and Benoist C (2002) How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 3:360-365. (Pubitemid 34308624)
142. Mauri C and Ehrenstein MR (2008) The 'short' history of regulatory B cells. Trends Immunol 29:34-40.
143. Mauri C, Gray D, Mushtaq N, and Londei M (2003) Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 197:489-501. (Pubitemid 36278604)
144. McGonagle D, Tan AL, Madden J, Taylor L, and Emery P (2008) Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) 47:865-867. (Pubitemid 351796374)
145. McKay J, Chwalinska-Sadowska H, Boling E, Valente R, Limanni A, Racewicz A, Wierzbinska-Zarowny D, Fernandez V, Zhong J, Zilberstein M, et al. (2005) Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogenous subject population. Arthritis Rheum 52:S710-S711.
146. McHeyzer-Williams LJ, Pelletier N, Mark L, Fazilleau N, and McHeyzer-Williams MG (2009) Follicular helper T cells as cognate regulators of B cell immunity. Curr Opin Immunol 21:266-273.
147. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, Agarwal S, Yin M, and Kelman A (2010) Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 37:917-927
148. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, and Bootsma H (2010) Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960-968.
149. Melchers F (2005) The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nat Rev Immunol 5:578-584.
150. Menard LC, Minns LA, Darche S, Mielcarz DW, Foureau DM, Roos D, Dzierszinski F, Kasper LH, and Buzoni-Gatel D (2007) B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated mechanism. J Immunol 179:4857-4866.
151. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, et al. (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222-233.
152. Mizoguchi A and Bhan AK (2006) A case for regulatory B cells. J Immunol 176:705-710. (Pubitemid 43099663)
153. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, and Bhan AK (1997) Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 186:1749-1756. (Pubitemid 27506287)
154. Mok CC, Ho LY, and To CH (2007) Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 34:1864-1868. (Pubitemid 350067647)
155. Molloy ES and Calabrese LH (2009) Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60:3761-3765.
156. Monneaux F, Dumortier H, Steiner G, Briand JP, and Muller S (2001) Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice. Int Immunol 13:1155-1163. (Pubitemid 32899158)
157. Mostoslavsky R, Alt FW, and Rajewsky K (2004) The lingering enigma of the allelic exclusion mechanism. Cell 118:539-544. (Pubitemid 39179707)
158. Navarra S, Guzman R, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan JL, et al. (2009) Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study (Abstract). Arthritis Rheum 60:3859.
159. Nemazee D and Weigert M (2000) Revising B cell receptors. J Exp Med 191:1813-1817. (Pubitemid 30390345)
160. Nestorov I, Papasouliotis O, Pena Rossi C, and Munafo A (2010) Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 99:524-538.
161. Neta R and Salvin SB (1974) Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J Immunol 113:1716-1725.
162. Neuberger MS (2008) Antibody diversification by somatic mutation: from Burnet onwards. Immunol Cell Biol 86:124-132.
163. Noronha AM, Liang Y, Hetzel JT, Hasturk H, Kantarci A, Stucchi A, Zhang Y, Nikolajczyk BS, Farraye FA, and Ganley-Leal LM (2009) Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol 86:1007-1016.
164. Noss EH, Hausner-Sypek DL, and Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33:1021-1026.
165. Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, et al. (2008) Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29:138-149.
166. O'Garra A, Chang R, Go N, Hastings R, Haughton G, and Howard M (1992) Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 22:711-717.
167. Obukhanych TV and Nussenzweig MC (2006) T-independent type II immune responses generate memory B cells. J Exp Med 203:305-310. (Pubitemid 43290839)
168. Oliver AM, Martin F, Gartland GL, Carter RH, and Kearney JF (1997) Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 27:2366-2374. (Pubitemid 27404323)
169. Oliver AM, Martin F, and Kearney JF (1999) IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells. J Immunol 162:7198-7207. (Pubitemid 29277691)
170. Olsen N (2007) Anti-TNF switching: effect on outcomes in patients with RA. Nat Clin Pract Rheumatol 3:430-431.
171. Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, and Nestorov I (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18:547-555.
172. Pendergraft WF, 3rd, Preston GA, Shah RR, Tropsha A, Carter CW, Jr., Jennette JC, and Falk RJ (2004) Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 10:72-79. (Pubitemid 38524701)
173. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, and Nobili B (2002) Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 116:465-467. (Pubitemid 34155523)
174. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, and Youinou P (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 1050:34-39. (Pubitemid 41129420)
175. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P, et al. (2010) Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 116:335-342.
176. Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG, Vissink A, and Ihrler S (2009) Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum 60:3251-3256.
177. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, and Bootsma H (2005) Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740-2750. (Pubitemid 41369102)
178. Pillai S and Cariappa A (2009) The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol 9:767-777.
179. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, and Tervaert JW (1999) Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 103:885-894. (Pubitemid 29297593)
180. Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M, Lombardi S, Pitzalis C, Beltrami CA, Curcio F, et al. (2008) Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2:38-43.
181. Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, and Dammacco F (2001) Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 167:21-29. (Pubitemid 32567756)
182. Ramos-Casals M, and Brito-Zeron P (2007) Emerging biological therapies in primary Sjogren's syndrome. Rheumatology (Oxford) 46:1389-1396. (Pubitemid 47317084)
183. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ, and BIOGEAS STUDY Group (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87:345-364.
184. Ramos-Casals M, Díaz-Lagares C, and Khamashta MA (2009a) Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 61:1281-1282.
185. Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, et al. (2010) Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 28:468-476.
186. Ramos-Casals M, Soto MJ, Cuadrado MJ, and Khamashta MA (2009b) Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 18:767-776.
187. Ravetch JV and Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275-290. (Pubitemid 32368037)
188. Renato GM (2009) B cell depletion in early rheumatoid arthritis: a new concept in therapeutics. Ann NY Acad Sci 1173:729-735.
189. Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, Francica S, Cavallo R, Alpa M, et al. (2008) Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 34:111-117.
190. Roche Press Release (2010) Roche and Biogen Idec decide to suspend Ocrelizumab treatment - rheumatoid arthritis development programme on hold. Available from http://www.roche.com/media/media-releases/med-cor-2010-03-08.htm.
191. Roll P, Palanichamy A, Kneitz C, Dorner T, and Tony HP (2006) Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54:2377-2386. (Pubitemid 44204997)
192. Saadoun D, Delluc A, Piette JC, and Cacoub P (2008) Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 20:23-28. (Pubitemid 351339428)
193. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, and Sato S (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453-1462. (Pubitemid 34596171)
194. Salliot C, Dougados M, and Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25-32.
195. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, and Dammacco F (2003) Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101:3818-3826. (Pubitemid 36857852)
196. Sanz I, Wei C, Lee FE, and Anolik J (2008) Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 20:67-82.
197. Sato S, Fujimoto M, Hasegawa M, and Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918-1927. (Pubitemid 38725103)
198. Sato S, Hasegawa M, Fujimoto M, Tedder TF, and Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635-6643.
199. Schwartzberg PL, Mueller KL, Qi H, and Cannons JL (2009) SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 9:39-46.
200. Sem M, Molberg O, Lund MB, and Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford) 48:968-971.
201. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, et al. (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 66:351-357. (Pubitemid 46579637)
202. Shapiro-Shelef M and Calame K (2005) Regulation of plasma-cell development. Nat Rev Immunol 5:230-242. (Pubitemid 40364824)
203. Sharma VR, Fleming DR, and Slone SP (2000) Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 96:1184-1186. (Pubitemid 30616893)
204. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, and Lipsky PE (2005) Identification and characterization of circulating human transitional B cells. Blood 105:4390-4398. (Pubitemid 40720786)
205. Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, and De Keyser F (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193-197.
206. Snapper CM, Yamada H, Smoot D, Sneed R, Lees A, and Mond JJ (1993) Comparative in vitro analysis of proliferation, Ig secretion, and Ig class switching by murine marginal zone and follicular B cells. J Immunol 150:2737-2745. (Pubitemid 23127523)
207. Sneller MC (2005) Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 52:1-5.
208. Stegeman CA, Tervaert JW, de Jong PE, and Kallenberg CG (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16-20. (Pubitemid 26230808)
209. Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, and Pradier O (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8:R129.
210. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, Metzger TE, Bixler SA, Hong YS, Ambrose CM, et al. (2005) BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 52:2080-2091. (Pubitemid 40994331)
211. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, et al. (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232.
212. Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, Lehane PB, and Agarwal S (2006) Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford) 45:1505-1513. (Pubitemid 44817056)
213. Stromatt S, Chopiak V, Dvoretskiy L, Koshukova G, Nasonov E, Povoroznyuk V, Stanislavchuk M, Leith P, and Alvarez D (2009) Sustained safety and efficacy of TRU-015 with continued retreatment of rheumatoid arthritis subjects following a phase 2B study (Abstract). American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals Scientific Meeting; 2009 Oct 17-21; Philadelphia. American College of Rheumatology, Atlanta, GA. Available at http://acr.confex.com/acr/2009/webprogram/Paper9626.html.
214. Sultan SM, Ng KP, Edwards JC, Isenberg DA, and Cambridge G (2008) Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol 26:887-893.
215. Suzan F, Ammor M, and Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000.
216. Szodoray P, Jellestad S, Teague MO, and Jonsson R (2003) Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome. Lab Invest 83:357-365. (Pubitemid 36350997)
217. Tak P, Rigby WFC, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen AC, Tyrrell H and Shaw TM (2009) Rituximab in combination with Methotrexate (MTX) significantly inhibits joint damage and improves clinical outcomes in patients with early active RA who are naïve to MTX: a randomized active comparator placebo-controlled trial (IMAGE). Arthritis Rheum 60 (Suppl):S238.
218. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, Rischmueller M, Nasonov E, Shmidt E, Emery P, et al. (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58:61-72.
219. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, and Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710-4718. (Pubitemid 32954353)
220. Tangye SG and Good KL (2007) Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J Immunol 179:13-19.
221. Tangye SG and Tarlinton DM (2009) Memory B cells: effectors of long-lived immune responses. Eur J Immunol 39:2065-2075.
222. Tedder TF (2009) CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 5:572-577.
223. Tedder TF and Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450-454. (Pubitemid 24272191)
224. Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JW, and van Laar JM (2009) Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies. Ann Rheum Dis 68:1075-1077.
225. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, and Tak PP (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67:917-925. (Pubitemid 351956651)
226. Tobón GJ, Pers JO, Youinou P, and Saraux A (2010) B cell-targeted therapies in Sjögren's syndrome. Autoimmun Rev 9:224-228.
227. Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:575-581.
228. Tumanov A, Kuprash D, Lagarkova M, Grivennikov S, Abe K, Shakhov A, Drutskaya L, Stewart C, Chervonsky A, and Nedospasov S (2002) Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 17:239-250. (Pubitemid 35279546)
229. UCB Press Release (2009) UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE). Available at: http://www.ucb.presscentre.com/content/detail.aspx?ReleaseID= 360&NewsAreaID=2&changeCurrentLocale=1.
230. van Vollenhoven RF, Emery P, Bingham CO, 3rd, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, et al. (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558-567.
231. Vanderlugt CL and Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2:85-95. (Pubitemid 37323232)
232. Viau M and Zouali M (2005) B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 114:17-26. (Pubitemid 39642786)
233. Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797-804.
234. Vinuesa CG and Cook MC (2001) The molecular basis of lymphoid architecture and B cell responses: implications for immunodeficiency and immunopathology. Curr Mol Med 1:689-725. (Pubitemid 33772944)
235. Vinuesa CG, Sanz I, and Cook MC (2009) Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol 9:845-857.
236. Vinuesa CG, Sze DM, Cook MC, Toellner KM, Klaus GG, Ball J, and MacLennan IC (2003) Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens. Eur J Immunol 33:297-305. (Pubitemid 36267593)
237. Visentini M, Granata M, Veneziano ML, Borghese F, Carlesimo M, Pimpinelli F, Fiorilli M, and Casato M (2007) Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 125:30-33. (Pubitemid 47374540)
238. von Boehmer H and Melchers F (2010) Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 11:14-20.
239. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, and Tak PP (2007) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56:772-778. (Pubitemid 46399424)
240. Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, Feller AC, Pitann S, Gause A, and Gross WL (2006) B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 65:859-864.
241. Voswinkel J, Müller A, and Lamprecht P (2005) Is PR3-ANCA formation initiated in Wegener's granulomatosis lesions? Granulomas as potential lymphoid tissue maintaining autoantibody production. Ann NY Acad Sci 1051:12-19. (Pubitemid 41362728)
242. Walsh M and Jayne D (2007) Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 72:676-682. (Pubitemid 47373785)
243. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, et al. (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61:1168-1178.
244. Wardemann H, Hammersen J, and Nussenzweig MC (2004) Human autoantibody silencing by immunoglobulin light chains. J Exp Med 200:191-199. (Pubitemid 38982178)
245. Wardemann H and Nussenzweig MC (2007) B-cell self-tolerance in humans. Adv Immunol 95:83-110. (Pubitemid 47381589)
246. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, and Nussenzweig MC (2003) Predominant autoantibody production by early human B cell precursors. Science 301:1374-1377. (Pubitemid 37075812)
247. Weber T, Trebst C, Frye S, Cinque P, Vago L, Sindic CJ, Schulz-Schaeffer WJ, Kretzschmar HA, Enzensberger W, Hunsmann G, et al. (1997) Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 176:250-254. (Pubitemid 27272877)
248. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, and Sanz I (2007) A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 178:6624-6633. (Pubitemid 46717447)
249. Weyand CM and Goronzy JJ (2003) Ectopic germinal center formation in rheumatoid synovitis. Ann NY Acad Sci 987:140-149. (Pubitemid 36584016)
250. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, and Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100:12319-12324. (Pubitemid 37271558)
251. Wolf SD, Dittel BN, Hardardottir F, and Janeway CA Jr (1996) Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 184:2271-2278. (Pubitemid 27023727)
252. Won WJ, Foote JB, Odom MR, Pan J, Kearney JF, and Davis RS (2006) Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol 177:6815-6823. (Pubitemid 44715046)
253. Won WJ and Kearney JF (2002) CD9 is a unique marker for marginal zone B cells, B1 cells, and plasma cells in mice. J Immunol 168:5605-5611.
254. Wuorimaa T and Käyhty H (2002) Current state of pneumococcal vaccines. Scand J Immunol 56:111-129. (Pubitemid 34779853)
255. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, and Jennette JC (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955-963.
256. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, and Tedder TF (2008a) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28:639-650. (Pubitemid 351636247)
257. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, and Tedder TF (2008b) B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223:284-299. (Pubitemid 351986191)
258. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, and Tedder TF (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 182:7459-7472.
259. Yang M, Sun L, Wang S, Ko KH, Xu H, Zheng BJ, Cao X, and Lu L (2010) Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol 184:3321-3325.
260. Yazawa N, Hamaguchi Y, Poe JC, and Tedder TF (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci USA 102:15178-15183. (Pubitemid 41513355)
261. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, and Ferraccioli G (2003) Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101:3827-3834. (Pubitemid 36857853)
262. Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G, and Baccarani M (2002a) Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 46:2252-2254; author reply 2254-2255.
263. Zaja F, Iacona I, Masolini P, Russo D, Sperotto A, Prosdocimo S, Patriarca F, de Vita S, Regazzi M, Baccarani M, et al. (2002b) B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 87:189-195. (Pubitemid 34160626)
264. Zandvoort A and Timens W (2002) The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 130:4-11.
265. Zhou LJ, Smith HM, Waldschmidt TJ, Schwarting R, Daley J, and Tedder TF (1994) Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol Cell Biol 14:3884-3894. (Pubitemid 24160795)